Please try another search
Incanthera plc, a dermatology and oncology therapeutics company, focuses on the dermatological formulation and delivery technologies for various indications. The company’s lead product Sol is a topical product for the treatment of solar keratosis and the prevention of skin cancers. It is also involved in the development of EP0015 for the treatment of lung, breast, ovarian, and prostate cancers, currently under lead and pre-clinical stage; Equin for the treatment of liver, brain, and pancreatic cancers, currently under pre-clinical stage; and Duo-C for the treatment of bladder and colorectal cancers, currently under lead stage. The company was founded in 2010 and is headquartered in Manchester, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Timothy Paul McCarthy | 66 | 2017 | Executive Chairman |
Caroline Diana Murray | 53 | 2022 | Non-Executive & Senior Independent Director |
Simon Ward | 55 | 2017 | CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review